ERBB2 and gastric cancer: Data from KEYNOTE-811 have led to European Medicines Agency (EMA) and FDA-approved pembrolizumab combined with trastuzumab and chemotherapy in patients with metastatic HER2- and PD-L1 dual-positive GC.